Manufacturing roundup: CellVax partners up with Theragent for PhII trial; Oxford Biomedica sells facility for $70M+
The cell therapy CDMO Theragent has roped in a manufacturing contract for a Phase II trial.
The company is working on CellVax Therapeutics’ immunotherapy candidate FK-PC101, a cell-based autologous cancer vaccine for prostate cancer patients who have a high rate of recurrence after prostatectomy. The size of the deal was not disclosed.
In an email to Endpoints News, Theragent COO Jeff Masten said the CDMO was selected after a consultant’s recommendation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.